OVOCA BIO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | -.--% |
|
-.--% | -.--% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 4.89M 4.57M 408M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -4.67M -417M | Net income 2022 | -5M -4.67M -417M | EV / Sales 2021 | - |
| Net cash position 2021 | 6.59M 6.15M 550M | Net cash position 2022 | 3.7M 3.46M 309M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.23
x | P/E ratio 2022 |
-0.87
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.54% |
More Fundamentals
* Assessed data
More press releases
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
28/06/2024
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock
